AZ And BMS Enter Diabetes By Inheriting Rights To GLP-1 Receptor Agonists From Eli Lilly Japan
This article was originally published in PharmAsia News
Executive Summary
Astra Zeneca and Bristol Myers Squibb acquired rights from Eli Lilly Japan for the manufacture and sale of Byetta (exenatide) and Bydureon (exenatide), two GLP-1 receptor agonists used for Type 2 diabetes.